TO THE EDITOR
We recently identified spontaneous T-cell responses against Bcl-2-derived peptides in patients suffering from cancers of different origin.
1 Myeloid cell factor-1 (Mcl-1) is a death-inhibiting member of the Bcl-2 family that is expressed in early monocyte differentiation and can promote viability on transfection into immature myeloid cells. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization of myeloid cells.
2 Elevated levels of Mcl-1 have been reported for a number of human cancers including prostate cancers, 3 pancreatic cancers, melanoma, breast cancers, ovarian cancer patients, and cervical cancer, as well as Bcell chronic lymphocytic leukemia (B-CLL) and in AML and ALL upon relapse. [4] [5] [6] In B-CLL patients, higher levels of Mcl-1 are strongly correlated with failure to achieve complete remission after single-agent therapy. In multiple myeloma, Mcl-1 plays an important role in the survival of malignant cells. 7 In this regard, it has been demonstrated that mice expressing an mcl-1 transgene under the control of its own promoter develop Bcell neoplasias with high frequency, ranging from follicular lymphoma to diffuse large-cell lymphoma. 8 Thus, the overexpression of Mcl-1 in many cancers of different origin and the fact that immune escape by downregulation or loss of expression of this protein would impair sustained tumor cell growth highlight Mcl-1 as a very attractive target for immunotherapy of cancer.
To investigate whether Mcl-1 is a natural target for T cells in cancer patients, we examined the protein sequence for the most probable HLA-A2 nona-and decamer peptide epitopes, using the main HLA-A3-specific anchor residues. 9 Subsequently, we synthesized six Mcl-1-deduced peptides (Mcl-1 [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] ) and scrutinized PBL from HLA-A3 þ cancer patients of different origin for reactivity against these peptides, taking advantage of the ELISPOT assay. This method has previously been shown to be highly efficient for the identification of tumor-specific CTL in cancer patients. 10, 11 Indeed, strong and frequent CTL responses were detected against two Mcl-1-derived peptides in cancer patients of different origin as exemplified in Figure 1a : an HLA-A3 þ breast cancer patient hosting a response against Mcl-1 95-103 and an HLA-A3 þ pancreatic cancer patient hosting a response against Mcl-1 300-308 (Figure 1a) . Overall, five out of six examined HLA-A3 þ breast cancer patients hosted an immune response against one of these two Mcl-1 peptides. Thus, five breast cancer patients hosted a response against Mcl-1 95-103 (responders are defined as the average number of antigen-specific cells7> 1 2 standard deviation 425/10 5 cells), and three patients hosted a response against Mcl-1 300-308 (Figure 1b) . Additionally, two out of two examined HLA-A3 þ pancreatic cancer patients hosted an immune response against the Mcl-1 95-103 peptide, whereas one of these also reacted against Mcl-1 300-308 . Additionally, we examined the PBL from six patients suffering from B-CLL and identified a response against Mcl-1 95-103 in two of these patients. As a control, PBL from 10 healthy HLA-A3 þ individuals were examined. Importantly, no responses were detected against either the Mcl-1 95-103 or the Mcl-1 300-308 peptide in any of the healthy donors (Figure 1b) . Similarly, no responses could be detected against any of the additional four Mcl-1-derived peptides in any of the cancer patients or healthy controls (data not shown).
In a recent study, we demonstrated CTL reactivity against the Bcl-2 protein in cancer patients. Together with the data presented here, this strongly suggests that cellular immune responses against antiapoptosis members of the Bcl-2 family represent a general phenomenon in cancer, and consequently that this group of proteins represents attractive universal target proteins for anticancer immunotherapy. The crucial role of Bcl-2 family of proteins, like Bcl-2 and Mcl-1, in cancer cell survival, implies that these proteins are highly relevant targets also for other therapeutic strategies in cancer treatment, for example, antisense oligonucleotides or small molecule inhibitors. However, our reports are the first to describe that the cellular immune system reacts against a member of this protein family, and that anticancer immunotherapy directed against this group of proteins, consequently, might be a novel effective way of attacking cancer. Furthermore, since this group of proteins is correlated with drug resistance, the combination of cytotoxic chemotherapy with immunotherapeutic targeting of Bcl-2 family of proteins might improve the efficacy of both treatments. In an attempt to maximize the impact of immunotherapy on disease progression, it is important to consider the expression profile and prognostic significance of the relevant target, for example, Mcl-1 and/or Bcl-2 in the particular disease, or disease stage. Thus, in some diseases like ovarian cancer, expression of Mcl-1, but not Bcl-2, is associated with advanced stage and poor survival for which reason Mcl-1 might be the prime antigen, whereas in diseases such as CLL, where Bcl-2 and Mcl-1 are cooverexpressed, 12 simultaneous targeting of both proteins may represent a more effective strategy than targeting either molecule alone. 
